As the world rushes to find a treatment for COVID-19, coronavirus patients are looking to secure a spot in studies for a potential treatment from Gilead, remdesivir, according to an Associated Press report.
According to the report, the National Institutes of Health is expanding its study, which is currently 440 patients strong.
While Gilead has been giving remdesivir to some patients on an emergency, case-by-case basis, CEO Dan O’Day says the studies could help get the treatment to more people.
“Many people have reached out to Gilead to advocate for access to remdesivir on behalf of friends and loved ones,” he wrote in a letter to the public. “I can only imagine how it must feel to be in that situation. We are taking the ethical, responsible approach.”
To read the full report on AP, click here.